<?xml version="1.0" encoding="UTF-8"?>
<p>Pyridostigmine is commonly used in myasthenia, but it loses its effectiveness over time. Salbutamol (β2‐adrenergic agonist) is effective in a cohort of human patients with congenital myasthenia, namely in those with specific gene mutations resulting in disruption of postsynaptic structure.</p>
